Imprint

by Jan | Oct 8, 2021

Imprint According to § 5 TMG   CORAT Therapeutics GmbH:Inhoffenstr. 7, 38124 Braunschweig, Germany Managing Director:Dr. Andreas Herrmann Contact:Phone: +49 1522 4047488E-Mail: info@corat-therapeutics.com Commercial Registry:HRB 208500, Registergericht...

Home

by Corat | Oct 8, 2021

How CORAT antibodies protect against severe COVID-19Recombinant human virus-neutralizing antibodies are the active component of the immunotherapy Read more From bench to bedsideExplore our clinical research projects Read more Learn more about concentrated...

CORAT Therapeutics GmbH announces partnership with Dermapharm Holding SE

by Jan | Jul 7, 2021 | 2021, News

For the fast and efficient delivery of its innovative drug COR-101 against COVID-19, CORAT Therapeutics GmbH announces the partnership with Dermapharm Holding SE, a manufacturer of branded pharmaceuticals. With its own development, production facilities as well as...

CORAT antibody COR-101 binds and inhibits all B.1.617 SARS-CoV-2 variants, including the fast proliferating “delta” variant

by Jan | Jun 22, 2021 | 2021, News

Our laboratory tests indicate that COR-101 recognizes the particularly aggressive new „delta” variant B.1.617.2, which is rapidly replacing the “alpha” variant B.1.1.7Dr. Andreas Herrmann, CEO, CORAT Therapeutics On May 10th, the WHO classified the B.1.617.2...

CORAT Therapeutics secures additional funding for Phase II clinical evaluation of its COVID-19 treatment

by Jan | Jun 3, 2021 | 2021, News

CORAT secures 12,7 Mio € from Lower Saxony State, private investors, and the German Ministry of Research and Education (BMBF). NBank Capital and private investors from Braunschweig, each having participated in previous financing rounds, renewed their investments. The...